Reply: Mesenchymal stromal (stem) cell therapy: An emerging immunomodulatory strategy for the adjunctive treatment of sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 3, 2014, Pages 364-365

  Kox, Matthijs ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; BACTERICIDAL ACTIVITY; CARCINOGENICITY; HUMAN; IMMUNE RESPONSE; LETTER; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

HUMANS; IMMUNIZATION; IMMUNOSUPPRESSION; SEPSIS;

EID: 84893550419     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1386LE     Document Type: Letter

References (10)

1. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 2013;187:1287-1293.
2. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28:2229-2238.
3. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012;302:L1003-L1013.
4. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047-1057.
5. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179:1855-1863.
6. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49.
7. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399.
8. Pène F, Grimaldi D, Zuber B, Sauneuf B, Rousseau C, El Hachem C, Martin C, Beläidouni N, Balloy V, Mira JP, et al. Toll-like receptor 2 deficiency increases resistance to Pseudomonas aeruginosa pneumonia in the setting of sepsis-induced immune dysfunction. J Infect Dis 2012;206:932-942.
9. Hoogerwerf JJ, Leendertse M, Wieland CW, de Vos AF, de Boer JD, Florquin S, van der Poll T. Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am J Respir Crit Care Med 2011;183:932-940.
10. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, B̈uscher D, Fibbe W, Foussat A, Kwa M, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies - bridging scientific observations and regulatory viewpoints. Cytotherapy 2013;15:753-759.